Skip to content
Clarity Pharmaceuticals – Radiopharmaceutical Therapies and Imaging
Clarity is a clinical stage radiopharmaceutical company developing next-generation products to improve treatment outcomes for children and adults with cancer
Clarity Pharmaceuticals - Radiopharmaceutical Therapies and ImagingClarity Pharmaceuticals - Radiopharmaceutical Therapies and Imaging
  • Home
  • Company
    • About Us
    • Careers
    • Senior Executive Team
    • Board of Directors
    • Advisory Board
  • Pipeline
    • Pipeline
    • SAR-bisPSMA
      • SAR-bisPSMA overview
      • 67Cu-SAR-bisPSMA
      • 64Cu-SAR-bisPSMA
    • SAR-Bombesin
    • SARTATE
    • Scientific Communications
    • Access to Products
  • Technology
    • SAR Technology
    • Copper Isotopes
    • Intellectual Property
  • News
  • Investor Centre
    • Overview
    • Reports & Presentations
    • Science Hat Podcast
    • Videos
  • LinkedIn
  • YouTube
  • Home
  • Company
    • About Us
    • Careers
    • Senior Executive Team
    • Board of Directors
    • Advisory Board
  • Pipeline
    • Pipeline
    • SAR-bisPSMA
      • SAR-bisPSMA overview
      • 67Cu-SAR-bisPSMA
      • 64Cu-SAR-bisPSMA
    • SAR-Bombesin
    • SARTATE
    • Scientific Communications
    • Access to Products
  • Technology
    • SAR Technology
    • Copper Isotopes
    • Intellectual Property
  • News
  • Investor Centre
    • Overview
    • Reports & Presentations
    • Science Hat Podcast
    • Videos
  • LinkedIn
  • YouTube

Daily Archives: May 1, 2018

Gamma Gazette: The challenges facing the Global Nuclear Medicine Market

In the News, NewsBy GlennMay 1, 2018

  Clarity Pharmaceuticals was featured in Gamma Gazette, a journal and newsletter issued by the Australian and New Zealand Society of Nuclear Medicine (ANZSNM), which provides a unique educational resource for all those working in the field of nuclear medicine as well as a means of publication for individual members’ research work. The article discusses…

Go to Top